Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Icon 2Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Icon 2Q11

Costs will grow in advance of Pfizer partnership revenues

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

ICON 2Q

2Q Revenues: $233 million (+4%)

2Q Earnings: $13 million (-43%)

YTD Revenues: 462 million (+4%)

YTD Earnings: $21 million (-52%)

Comments: ICON’s backlog passed $2.0 billion for the first time As a result of its new long-term partnership with Pfizer, the company anticipates increased 3Q expenses without immediate offsetting revenue gains. Costs will also increase in 4Q, but Pfizer-related revenues are expected to build in that quarter. Direct costs were up 15% in 2Q to $151 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics